Early clinical development of a novel anti-angiogenic monoclonal antibody directed against A5B1 integrin for treatment of solid tumors

被引：0
|
作者：
Finck, BK [1 ]
机构：
[1] Prot Design Labs, Fremont, CA USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：27 / 28
页数：2
相关论文
共 50 条
  • [1] Preclinical evaluation of an anti-alpha 5 beta 1 integrin antibody as a novel anti-angiogenic agent
    Ramakrishnan, Vanitha
    Bhaskar, Vinay
    Law, Debbie A.
    Wong, Melanie H. L.
    DuBridge, Robert B.
    Breinberg, Danna
    O'Hara, Christopher
    Powers, David B.
    Liu, Gao
    Grove, Jennifer
    Hevezi, Peter
    Cass, Kellie M.
    Watson, Susan
    Evangelista, Ferdinand
    Powers, Rick A.
    Finck, Barbara
    Caras, Margaret Wills Ingrid
    Fang, Yuni
    McDonald, Donald
    Johnson, Dale
    Murray, Richard
    Jeffry, Ursula
    JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, 2006, 5 (04) : 273 - 286
  • [2] Development of an anti-angiogenic therapeutic antibody against LRG1
    Tripathi, Vineeta
    George, Jestin
    Davis, Sterenn
    Liyanage, Sidath E.
    Bainbridge, James W. B.
    Greenwood, John
    Moss, Stephen E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [3] Anti-angiogenic Mechanism of IPS-05002, a Novel Antagonist against Integrin α5β1, Determined by ProteoChip-based Antibody Array
    Kim, Min-A
    Kang, In-Cheol
    BIOCHIP JOURNAL, 2016, 10 (03) : 174 - 181
  • [4] Anti-angiogenic mechanism of IPS-05002, a novel antagonist against integrin a5β1, determined by ProteoChip-based antibody array
    Min-A Kim
    In-Cheol Kang
    BioChip Journal, 2016, 10 : 174 - 181
  • [5] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
    Haddley, K.
    DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
  • [6] Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
    Camidge, D. Ross
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (08) : 1167 - 1176
  • [7] Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
    Cruz, Esteban
    Kayser, Veysel
    BIOLOGICS-TARGETS & THERAPY, 2019, 13 : 33 - 51
  • [8] Preclinical development of NGM438, a novel anti-LAIR1 antagonist monoclonal antibody for the treatment of collagen-rich solid tumors.
    He, Sisi
    Huang, Jiawei
    Rodriguez, Leticia
    Cortez, Czrina
    Li, Betty
    Ho, Carmence
    Ashique, Amir
    Mondal, Kalyani
    Lin, Vicky
    Roda, Julie
    Tian, Hui
    Wang, Yan
    Fan, Bin
    Mikaelian, Igor
    Sissons, James
    Rivera, Lee
    Gibbons, Don
    Sitrin, Jonathan
    CANCER RESEARCH, 2022, 82 (12)
  • [9] A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
    Mateo, J.
    Berlin, J.
    de Bono, J. S.
    Cohen, R. B.
    Keedy, V.
    Mugundu, G.
    Zhang, Lianglin
    Abbattista, A.
    Davis, C.
    Stampino, C. Gallo
    Borghaei, H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1039 - 1046
  • [10] A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
    J. Mateo
    J. Berlin
    J. S. de Bono
    R. B. Cohen
    V. Keedy
    G. Mugundu
    Lianglin Zhang
    A. Abbattista
    C. Davis
    C. Gallo Stampino
    H. Borghaei
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1039 - 1046
12345